Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AQST | INST-CLUSTER | mixed | 4/10 | Institutional activity in Aquestive Therapeutics during Q2 2026 was mixed: 5 buyers added $7.1M in net new positions (le | Aug 15, 2026 |
| ABUS | INST-CLUSTER | mixed | 4/10 | Three asset managers (Fidelity, Russell, Nuveen) added small positions in ABUS during Q2 2026, totaling $2.0M in net buy | Aug 15, 2026 |
| INCY | CLUSTER | bearish | 4/10 | Two top R&D executives at Incyte sold a combined $1.57M in stock over a 7-day window. President Pablo Cagnoni sold $1.30 | Aug 15, 2026 |
| EWTX | CLUSTER | neutral | 3/10 | CEO Kevin Koch and General Counsel John Moore sold a combined ~$468K in open-market sales on August 12, 2026, following | Aug 15, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Two C-suite insiders at Corcept Therapeutics sold shares on August 10, 2026, totaling $662K in open-market sales. The sa | Aug 15, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold ~$7.1M in open-market shares over two days (Aug 12-13), exercising options at $135.42 and imm | Aug 15, 2026 |
| BSEM | 3 | neutral | 2/10 | Mark A. Glickman filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting 7,671 restricted st | Aug 14, 2026 |
| CCCC | 144 | neutral | 3/10 | Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice of intent to sell a | Aug 14, 2026 |
| BSEM | 3 | neutral | 2/10 | Jason Matuszewski, the CEO of BioStem Technologies, filed a Form 3 initial statement of beneficial ownership, disclosing | Aug 14, 2026 |
| IRON | CLUSTER | neutral | 2/10 | Two senior insiders at Disc Medicine (IRON), the COO and Chief Legal Officer, sold a combined $466K in open-market sales | Aug 14, 2026 |
| OVID | 144 | neutral | 3/10 | Jeffrey A. Rona, an affiliated stockholder of Ovid Therapeutics, filed a Form 144 notice of intent to sell up to 150,000 | Aug 14, 2026 |
| ACHV | 8-K | bearish | 5/10 | Achieve Life Sciences entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) | Aug 14, 2026 |
| ZNTL | 8-K | bearish | 6/10 | Zentalis Pharmaceuticals priced a public offering of 23,000,000 shares of common stock at $3.50 per share, with an under | Aug 14, 2026 |
| PHIO | DEFA14A | neutral | 3/10 | Phio Pharmaceuticals Corp. filed a DEFA14A (additional definitive proxy soliciting materials) for its 2026 Annual Meetin | Aug 14, 2026 |
| OPTH | 6-K | bearish | 6/10 | Optimi Health Corp. entered a $100M at-the-market equity line of credit (ELOC) with Seven Knots, LLC, issuing a $1.5M co | Aug 14, 2026 |
| GRML | 10-Q/A | neutral | 2/10 | Greenland Mines Ltd filed Amendment No. 1 to its Q1 2026 Form 10-Q to revise certain disclosures in response to SEC comm | Aug 14, 2026 |
| KRYS | 144 | neutral | 2/10 | Director Dino A. Rossi filed a Form 144 notice of intent to sell 25,000 shares of Krystal Biotech common stock through G | Aug 14, 2026 |
| BIVI | S-1/A | bearish | 7/10 | BioVie Inc. filed Amendment No. 3 to its S-1 registration statement for a best-efforts offering of up to 16,025,641 shar | Aug 14, 2026 |
| WLK | PRESS-RELEASE | neutral | 2/10 | Westlake Corporation declared a regular quarterly dividend of $0.533 per share, payable September 10, 2026. This is a ro | Aug 14, 2026 |
| DYN | 144 | neutral | 4/10 | Atlas Venture, a founding investor in Dyne Therapeutics, filed multiple Form 144 notices on August 14, 2026, signaling i | Aug 14, 2026 |
| CCCC | INST-CLUSTER | bullish | 6/10 | Eight major institutional investors, including BlackRock, State Street, and Fidelity, more than doubled their C4 Therape | Aug 14, 2026 |
| ABEO | INST-CLUSTER | bullish | 5/10 | Abeona Therapeutics saw a strong institutional accumulation cluster in Q2 2026, with 6 buyers adding $12.5M in net new p | Aug 14, 2026 |
| ISPC | 8-K | bearish | 7/10 | iSpecimen Inc. (ISPC) entered into a $2,000,000 cash consulting agreement with IR Agency LLC for marketing and advertisi | Aug 14, 2026 |
| BYSI | 8-K | neutral | 4/10 | BeyondSpring reported Q2 2026 financial results with a net loss from continuing operations of $1.8M, roughly in line wit | Aug 14, 2026 |
| CNTN | 8-K | mixed | 5/10 | Canton Strategic Holdings reported its first-ever operating revenue of $1.5M for Q2 2026, transitioning from zero revenu | Aug 14, 2026 |
| BYSI | PRESS-RELEASE | neutral | 5/10 | BeyondSpring reported Q2 2026 net loss of $1.8M from continuing operations, essentially flat YoY, with no revenue. The k | Aug 14, 2026 |
| SEPN | CLUSTER | bearish | 6/10 | Two insiders at Septerna sold a combined $32.83M in open-market transactions within a 7-day window, representing 1.6% of | Aug 14, 2026 |
| ATNM | 8-K | bearish | 6/10 | Actinium Pharmaceuticals received NYSE Regulation acceptance of its compliance plan, granting a maximum extension throug | Aug 14, 2026 |
| MRK | COURT-RULING | neutral | 3/10 | The District of New Jersey lifted the stay on Merck's third-party action against Cencora in the Humana antitrust litigat | Aug 14, 2026 |
| OPTH | 6-K | bearish | 6/10 | Optimi Health Corp. filed its unaudited interim financial statements for the 9-month period ended June 30, 2026, reporti | Aug 14, 2026 |